KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Inventory (2016 - 2025)

Historic Inventory for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Biomarin Pharmaceutical's Inventory rose 1719.9% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 1719.9%. This contributed to the annual value of $1.2 billion for FY2024, which is 1133.24% up from last year.
  • Biomarin Pharmaceutical's Inventory amounted to $1.4 billion in Q3 2025, which was up 1719.9% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Inventory peaked at $1.4 billion during Q3 2025, and registered a low of $711.0 million during Q2 2021.
  • In the last 5 years, Biomarin Pharmaceutical's Inventory had a median value of $975.5 million in 2023 and averaged $1.0 billion.
  • In the last 5 years, Biomarin Pharmaceutical's Inventory crashed by 441.98% in 2021 and then surged by 2383.89% in 2024.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Inventory stood at $776.7 million in 2021, then increased by 15.12% to $894.1 million in 2022, then increased by 23.83% to $1.1 billion in 2023, then grew by 11.33% to $1.2 billion in 2024, then increased by 12.13% to $1.4 billion in 2025.
  • Its Inventory stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.